Structured treatment interruptions in HIV infection: benefit or disappointment?

References

• Palella FJ Jr, Delaney KM, Moorman AC, etal Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Out-patient Study Investigators. N Engl. Merl 338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• •Recently observed declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
   Google Scholar
• Fiepp M, Schiffer V, Weber R, Hirschel B.Modem antiHIV therapy. Swiss Merl Wkly131(15–16), 207–213 (2001).
   Google Scholar
• Finzi D, Hermankova M, Pierson T, etal.Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278 (5341), 1295–3000 (1997).
   PubMed Web of Science ®Google Scholar
• Wong JK, Hezareh M, Gunthard HF, etal Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278(5341), 1291–1295 (1997).
   PubMed Web of Science ®Google Scholar
• •Documents the persistence of viral reservoirs despite prolonged successful suppression of viral replication with antiretroviral therapy which was attributed to viral latency rather than drug failure.
   Google Scholar
• Chun TVV, Stuyver L, Mizell SB, et al Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl Acad. Sci. USA 94(24), 13193–131937 (1997).
   PubMed Web of Science ®Google Scholar
• Jain RG, Furfine ES, Pedneault L, WhiteAJ, Lenhard JM. Metabolic complications associated with antiretroviral therapy. Antiviral Res. 51(3), 151–77 (2001).
   PubMed Web of Science ®Google Scholar
• Lucas GM, Chaisson RE, Moore RD.Highly active antiretroviral therapy in a large urban clinic: risk factors for virologicfailure and adverse drug reactions. Ann. Intern. Merl 131(2), 81–87 (1999).
   PubMed Web of Science ®Google Scholar
• Binswanger HP Public health. HIV/AIDS treatment for millions. Science 292(5515), 221–223 (2001).
   PubMed Web of Science ®Google Scholar
• Klein MR, van Baalen CA, Holwerda AM, etal Kinetics of Gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. Exp. Merl 181(4), 1365–1372 (1995).
   PubMed Web of Science ®Google Scholar
• Brodie SJ, Lewinsohn DA, Patterson BK, etal In vivo migration and function of transferred HIV-1-specific cytotoxic T-cells [See comments]. Nature Merl 5(1), 34–41 (1999).
   PubMed Web of Science ®Google Scholar
• Daar ES, Moudgil T, Meyer RD, Ho DD.Transient high levels of viremia in patients with primary human immunodeficiency virus Type 1 infection. N Eng/. I Med. 324(961), 961–964 (1991).
   PubMedGoogle Scholar
• Clark SJ, Saag MS, Decker WD, etal High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl. I Merl 324(954), 954–960 (1991).
   PubMedGoogle Scholar
• Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus Type 1 infection.Viral. 68(9), 6103–6110 (1994).
   PubMed Web of Science ®Google Scholar
• •The level of HIV-1-specific cytotoxic T-cell (CTL) activity in five patients with acute HIV-I infection paralleled the efficiency of control of primaryviremia.
   Google Scholar
• Musey L, Hughes J, Schacker T, etal Cytotoxic-T-cell responses, viral load and disease progression in early human immunodeficiency virus Type 1 infection [see comments] N Eng/. I Med. 337(18), 1267–1274 (1997).
   PubMed Web of Science ®Google Scholar
• •During acute HIV-1 infection, the induction of virus-specific cytotoxic T-lymphocytes is involved in the control viral replication and is associated with slower declines in CD4+ cell counts, hence delaying the progression of HIV-1 disease.
   Google Scholar
• Koup RA, Safrit JT, Coa Y, etal Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus Type 1 syndrome. j Vim'. 684,650–655 (1994).
   Google Scholar
• •Demonstrates that cellular immunity is involved in the initial control of virus replication in primary HIV-1 infection and indicates a role for CTL in protective immunity to HIV-I in vivo.
   Google Scholar
• Borrow P, Lewicki H, Wei X, etal Antiviral pressure exerted by HIV-1-specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [see comments]. Nature Merl 3(2), 205–211 (1997).
   PubMed Web of Science ®Google Scholar
• Wilson JD, Imami N, Watkins A, etal I riss of CD4+ T-cell proliferative ability but not loss of human immunodeficiency virus Type 1 specificity equates with progression to disease. J Infect Dir. 182(3), 792–798 (2000).
   PubMed Web of Science ®Google Scholar
• Kuroda MJ, Schmitz JE, Charini WA, etal Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. Imurunol 162 (9), 5127–5133 (1999).
   PubMed Web of Science ®Google Scholar
• Oxenius A, Price DA, Easterbrook PJ, etal Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T-lymphocytes. Proc. Natl Acad. Sci USA 97(7), 3382–3387 (2000).
   PubMed Web of Science ®Google Scholar
• Pantaleo G, Demarest JF, Soudeyns H, etal Major expansion of CD8+ T-cells with a prominant VP usage during the primary response to HIV. Nature 370,463–467 (1994).
   PubMed Web of Science ®Google Scholar
• Schmitz JE, Kuroda MJ, Santra S, etal.Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283(5403), 857–860 (1999).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates for the first time the directinvolvement of CD8+ T-cells in control of simian immunodeficiency virus (SIV) replication in viva Depletion of CD8+ T-cells in vivo led to increasing levels of viral replication and restoration of CD8+ T-cells was associated with decreased viral replication.
   Google Scholar
• Pitcher CJ, Quittner C, Peterson DM, etal. HIV-1-specific CD4+ T-cells are detectable in most individuals with active HIV-1 infection but decline with prolonged viral suppression [see comments]. Nature Med 5(5), 518–525 (1999).
   PubMed Web of Science ®Google Scholar
• •This study showed for the first time that cytokine-producing HIV-specific CD4+ T-cells can be detected in a majority of HIV infected individuals. The frequency of these cells declined with prolonged drug-mediated suppression and was at the highest levels in patients with good virological control in the absence of treatment.
   Google Scholar
• Rosenberg ES, Billingsley JM, CaliendoAM, etal. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia [see comments]. Science 278(5342), 1447–1450 (1997).
   PubMed Web of Science ®Google Scholar
• •This study showed that HIV-specific proliferative CD4+ T-cell responses are inversely correlated with the plasma viremia in HIV-infected individuals.
   Google Scholar
• Price D, Goulder PJR, Klenerman P, etal Positive selection of cytotoxic T-cell escape variants during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 94,1890–1895 (1997).
   PubMed Web of Science ®Google Scholar
• Kalams SA, Buchbinder SP, Rosenberg ES, etal Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus Type 1 infection. j Viral. 73(8), 6715–6720 (1999).
   PubMed Web of Science ®Google Scholar
• Harrer T, Harrer E, Kalams SA, et al Strong cytotoxic T-celland weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV Type 1 infection. AIDS Res. Hum Retroviruses 12(7), 585–592 (1996).
   PubMed Web of Science ®Google Scholar
• Harrer T, Harrer E, Kalams SA, etal Cytotoxic T-lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. j Immunol 156(7), 2616–2623 (1996).
   Web of Science ®Google Scholar
• Kelleher AD, Long C, Holmes EC, etal. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T-lymphocyte responses. I EAp. Med 193(3), 375–386 (2001).
   PubMed Web of Science ®Google Scholar
• Goulder PJR, Phillips RE, Colbert B, et al Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3212–3217 (1997).
   Google Scholar
• Ogg GS, Jin X, Bonhoeffer S, etal. Quantitiation of HIV-1 specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science 279,2103–2106 (1998).
   PubMed Web of Science ®Google Scholar
• Betts MR, Ambrozak DR, Douek DC, etal. Analysis of total human immunodeficiency virus (HIV)-specific CD4() and CD8() T-cell responses: relationship to viral load in untreated HIV infection. j Vim!. 75(24), 11983–11991 (2001).
   Google Scholar
• •A comprehensive analysis of HIV-specific CD4+ and CD8+ T-cell frequencies was performed in untreated HIV-infected individuals. No correlation between the degree of viral replication and the level of HIV-specific T-cell frequencies was observed.
   Google Scholar
• Goulder PJ, Brander C, Tang Y, etal.Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412(6844), 334–338 (2001).
   Google Scholar
• Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann. Intern. Med. 134 (10), 978–996 (2001).
   PubMedGoogle Scholar
• Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: cellular and humoral immune responses. Ann. Intern. Med. 134(9 Pt 1), 761–776 (2001).
   PubMedGoogle Scholar
• Tang J, Costello C, Keet IP, etal. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus Type 1 infection. AIDS Res. Hum. Retro viruses 15(4), 317–324 (1999).
   PubMed Web of Science ®Google Scholar
• Migueles SA, Laborico AC, Shupert WL, etal HIV-specific CD8+ T-cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immuno13(11), 1061–1068 (2002).
   Google Scholar
• •Describes, for the first time, a distinct immunological feature associated with long-term nonprogression; HIV-specific CD8+ T-cells from LTNP exhibited marked proliferative potential ascompared with patients with less optimal control of viral replication.
   Google Scholar
• Vila J, Nugier F, Bargues G, et al Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 350(9078), 635–636 (1997).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Rosenberg E, Lieberman J, etal. Control of HIV despite the discontinuation of antiretroviral therapy [letter]. NEng!.J Med 340(21), 1683–1684 (1999).
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease [see comments]. Science 277(5322), 112–116 (1997).
   PubMed Web of Science ®Google Scholar
• •Highly active antiretroviral therapy increases CD4+ cell numbers in distinct phases: an early increase of memory CD4+ cells followed by a rise of naive CDT cells. This reconstitution of CD4+ T-cells during antiretroviral therapy can reverse HIV-driven activation and CD4+ T-cell defects in advanced HIV-infected patients.
   Google Scholar
• Hatano H, Vogel S, Yoder C, etal. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS14(10), 1357–1363 (2000) (In Press).
   Google Scholar
• Ho DD. Time to hit HIV, early and hard. N. Engl. Med 333(7), 450–451 (1995).
   PubMed Web of Science ®Google Scholar
• Ruiz L, Martinez-Picado J, Romeu J, etal. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS14 (4), 397–403 (2000).
   Google Scholar
• Ruiz L, Carcelain G, Martinez-Picado J, etal. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15(9), F19-27 (2001).
   Google Scholar
• Garcia F, Plana M, Ortiz GM, etal The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. A/DS15 (9), F29-40 (2001).
   Google Scholar
• Ortiz GM, Wellons M, Brancato J, etal Structured antiretroviral treatment interruptions in chronically HIV-1 infected subjects. Proc. Natl Acad. Su. USA 981, 3288–3293 (2001).
   Google Scholar
• Ortiz GM, Nixon DF, Trkola A, et al HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. Clin. Invest. 104(6), R13-18 (1999)
   Google Scholar
• Carcelain G, Tubiana R, Samri A, etal. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV Type 1 infection. J. Vim/. 75(1), 234–241 (2001).
   Google Scholar
• Montaner U. Structured treatment interruptions to control HIV-1 and limit drug exposure. Trends Immunol 2292–2296 (2001).
   Google Scholar
• Altfeld M, Walker BD. Less is more? STI in acute and chronic HIV-1 infection. Nature Merl 7(8), 881–884 (2001).
   PubMed Web of Science ®Google Scholar
• Allen TM, Kelleher AD, Zaunders J, Walker BD. STI and beyond: the prospects of boosting antiHIV immune responses. Tends Immunol 23(9), 456–460 (2002).
   PubMed Web of Science ®Google Scholar
• Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JA/V/A 286(23), 2981–2987 (2001).
   Google Scholar
• Izopet J, Massip P, Souyris C, etal Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS 14(15), 2247–2255 (2000).
   PubMed Web of Science ®Google Scholar
• Miller V, Sabin C, Hertogs K, etal. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14(18), 2857–2867 (2000).
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS'13(18), 2541–2546 (1999).
   Google Scholar
• Rosenberg ES, Altfeld M, Poon SH, etal Immune control of HIV-1 after early treatment of acute infection. Nature407(6803), 523–526 (2000).
   PubMedGoogle Scholar
• •Eight subjects initiated antiretroviral therapy during acute infection, followed by one or two supervised treatment interruptions. Despite rebound in viremia, all subjects were able to achieve at least a transient steady-state of well-controlled viremia off therapy which was associated with increased virus-specific CTL frequencies and maintained T-helper cell responses.
   Google Scholar
• Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus Type 1 infection. J. Virol. 75(21), 10200–10207 (2001).
   PubMed Web of Science ®Google Scholar
• Altfeld M, Allen TM, Yu XG, etal HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420 (6914), 434–439 (2002).
   PubMed Web of Science ®Google Scholar
• •Follows on a patient from [53] who experienced a marked increase in of plasma viremia after prolonged immune containment. The reason for this virological breakthrough was an HIV-1 superinfection, despite the prevailing broad and strong HIV-specific T-cell immunity The lack of crossprotective immunity for closely related HIV-1 strains has implications for vaccine development.
   Google Scholar
• Lori F, Lewis MG, Xu J, et al. Control ofSIV rebound through structured treatment interruptions during early infection. Science 290 (5496), 1591–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Lifson JD, Rossio JL, Arnaout R, et al Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.Virol. 74(6), 2584–2593 (2000).
   Web of Science ®Google Scholar
• •In this animal study, the time of initiation and duration of postinoculation antiretroviral treatment resulting in augmented virological control was analyzed. Transient postinoculation treatment led to either control of viral replication below the limit of detection or to downrnodulation of the level of plasma viremia following treatment cessation. The results suggest effective control of SW infection may occur if the initial exposure occurs at low viral burden.
   Google Scholar
• Hel Z, Venzon D, Poudyal M, etal. Viremia control following antiretroviral treatment and therapeutic immunization during primary 51V2 51 infection of macaques. Nature Med. 6 (10), 1140–1146 (2000).
   PubMed Web of Science ®Google Scholar
• Hel Z, Nacsa J, Tryniszewska E, etal Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre-and postchallenge CD4+ and CD8+ T-cell responses. J. Immunol 169(9), 4778–4787 (2002).
   PubMed Web of Science ®Google Scholar
• Kinloch-De Loes S, Hirschel BJ, Hoen B, etal A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl. Merl 333(7), 408–413 (1995).
   PubMed Web of Science ®Google Scholar
• Watson A, McClure J, Ranchalis J, et al Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV Type 2-infected macaques. AIDS Res. Hum. Retivviruses13(10,1375-1381 (1997).
   Google Scholar
• Altfeld M, Rosenberg ES, Shankarappa R, etal Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. I Exp. Merl 193(2), 169–180 (2001).
   PubMed Web of Science ®Google Scholar
• Mellors JW, Rinaldo CR Jr, Gupta P, etal Prognosis in HIV-1 infection predicted by the quantity of virus in plasma [see comments]. Science 272 (5265), 1167–1170 (1996) [erratum appears in Science 275(5296), 14 (1997)
   PubMedGoogle Scholar
• •Analyzed the relationship between viremia and clinical outcome in a cohort of HIV-infected individuals over 10 years. The risk of AIDS and death was directly related to plasma viral load at study entry and plasma viral load was a better predictor of progression to AIDS and death than was the number of CD4+ T-cells.
   Google Scholar
• Ogg GS, Jin X, Bonhoeffer S, et al Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T-lymphocytes after combination antiretroviral therapy. J. Viral 73(1), 797–800 (1999).
   PubMed Web of Science ®Google Scholar
• Casazza JP, Betts MR, Picker LJ, Koup RA. Decay kinetics of human immunodeficiency virus-specific CD8(+) T-cells in peripheral blood after initiation of highly active antiretroviral therapy. J. Viral 75(14), 6508–6516 (2001).
   PubMed Web of Science ®Google Scholar
• Neumann AU, Tubiana R, Calvez V, etal. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 13(6), 677–683 (1999).
   PubMed Web of Science ®Google Scholar
• Jubault V, Burgard M, Le Corfec E, etal High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy. AIDS12 (17), 2358–2359 (1998).
   Google Scholar
• Staszewski S, Miller V, Sabin C, et al. Rebound of HIV-1 viral load after suppression to very low levels. AIDS12(17), 2360 (1998).
   Google Scholar
• Papasavvas E, Ortiz GM, Gross R, et al. Enhancement of human immunodeficiency virus Type 1-specific CD4 and CD8 T-cell responses in chronically infected persons after temporary treatment interruption. Infect. Dis. 182(3), 766–775 (2000).
   Web of Science ®Google Scholar
• Mollet L, Li TS, Samri A, etal Dynamics of HIV-specific CD8+ T-lymphocyte responses with changes in viral load. J. Immunol. 165,1692–1704 (2000).
   PubMed Web of Science ®Google Scholar
• Dybul M, Chun TW, Yoder C, etal Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters. Proc. Natl Acad. Sc]. USA 981,5161–5166 (2001).
   Google Scholar
• •In this pilot study, short-cycle (1 week off, 1 week on) intermittent therapy maintained suppression of plasma viremia as well as HIV replication in reservoirs and preserved CD4+ T-cell counts. A decrease in serum cholesterol and triglyceride levels was observed, suggesting that such a strategy might reduce drug-toxicity and costs for HIV-infected individuals.
   Google Scholar
• Davey RT Jr, Bhat N, Yoder C, etal. HIV-1 and T-cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sc]. USA 96(26), 15109–15114 (1999).
   PubMed Web of Science ®Google Scholar
• Martinez-Picado J, Morales-Lopetegi K, Wrin T, etal Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 16(6), 895–899 (2002).
   PubMed Web of Science ®Google Scholar
• Dybul M, Daucher M, Jensen MA, et al Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. J. Viral 77(5), 3229–3237 (2003).
   PubMed Web of Science ®Google Scholar
• Fagard C, Oxenius A, Ganthard H, et al A prospective trial of structured treatment interruptions in HIV infection. Arch. Intern. Med. (2002) (In Press).
   Google Scholar
• •First prospective large-scale clinical study on STI in chronically infected individuals. The main findings of this trial are that 17% of the patients exhibited a pVL below 5000 copies/m1 and 1 year after final cessation of therapy 8% of the total study cohort remained below 5000 copies/m1 Low preART pVL and lack of viral rebounds during the two week treatment interruptions predicted a low pVL after final cessation of therapy. The median CD4 count decreased during the first three months following final treatment stop but stabilized thereafter.
   Google Scholar
• Perrin L, Yerly S, Fagard C, etal Antiviral Ther. 7S59 (2001) (Abstract).
   Google Scholar
• Metzner KJ, Bonhoeffer S, Fischer M, etal Antiviral Ther. 7S73 (2002) (Abstract).
   Google Scholar
• Oxenius A, Price DA, Gunthard HF, etal Stimulation of HIV specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV-infection. Proc. Natl Acad. Sc]. USA (2002) (In Press).
   PubMedGoogle Scholar
• Lori F, Maserati R, Foli A, et al Structured treatment interruptions to control HIV-1 infection. Lancet355(9200), 287–288 (2000).
   Google Scholar
• Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic and toxicity parameters. Proc. Natl Acad. Sc]. USA 98(26), 15161–15166 (2001).
   PubMed Web of Science ®Google Scholar
• Fidler SJ, Dorrell L, Ball S, etal An early antigen-presenting cell defect in HIV-1-infected patients correlates with CD4 dependency in human T-cell clones. Immunology89(1), 46–53 (1996).
   Google Scholar
• Lore K, Sonnerborg A, Brostrom C, etal Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS16(5), 683–692 (2002).
   Google Scholar
• Andrieu M, Chassin D, Desoutter JF, etal. Downregulation of major histocompatibility class I on human dendritic cells by HIV Nef impairs antigen presentation to HIV-specific CD8+ T-lymphocytes. AIDS Res. Hum. Retroviruses 17(14), 1365–1370 (2001).
   PubMed Web of Science ®Google Scholar
• Klenerman P and Zinkernagel RM. Original antigenic sin impairs cytotoxic T-lymphocyte responses to viruses bearing variant epitopes [see comments]. Nature 394(6692), 482–485 (1998).
   PubMed Web of Science ®Google Scholar
• Virelizier JL, Allison AC, Schild GC. Antibody responses to antigenic determinants of influenza virus hemagglutinin. II. Original antigenic sin: a bone marrow-derived lymphocyte memory phenomenon modulated by thymus-derived lymphocytes. J. Exp. Med. 140(6), 1571–1578 (1974).
   PubMed Web of Science ®Google Scholar
• Fazekas de St G, Webster RG. Disquisitions on original antigenic Sin. II. Proof in lower creatures. J. Exp. Med. 124(3), 347–361 (1966).
   PubMed Web of Science ®Google Scholar
• Fazekas de St G, Webster RG. Disquisitions of original antigenic Sin. I. Evidence in man. J Eyp Med. 124(3), 331–345 (1966).
   PubMed Web of Science ®Google Scholar
• Webster RG. Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J. Immunol 97(2), 177–183 (1966).
   PubMed Web of Science ®Google Scholar
• Phillips RE, Rowland-Jones S, Nixon DF, etal Human immunodeficiency virus genetic variation that can escape cytotoxic T-cell recognition [see comments]. Nature 354(6353), 453–459 (1991).
   PubMed Web of Science ®Google Scholar
• O'Connor DH, Allen TM, Vogel TU, etal Acute phase cytotoxic T-lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nattily Merl 8(5), 493–499 (2002).
   PubMed Web of Science ®Google Scholar
• Allen TM, O'Connor DH, Jing P, etal. Tat-specific cytotoxic T-lymphocytes select for SW escape variants during resolution of primary viremia. Nature 407(6802), 386–390 (2000).
   PubMed Web of Science ®Google Scholar
• Altfeld M, van Lunzen J, Frahm N, et al Expansion of pre-existing, lymph node-localized CD8+ T-cells during supervised treatment interruptions in chronic HIV-1 infection. J. Clin. Invest. 109(6), 837–843 (2002).
   PubMed Web of Science ®Google Scholar
• Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nature Med 9(1), 27–32 (2003).
   PubMed Web of Science ®Google Scholar
• •Demonstrated that effective and durable SW-specific cellular and humoral immunity, associated with maintenance of reduced viremia can be elicited by vaccination with chemically inactivated SW loaded on autologous dendritic cells.
   Google Scholar
• Lisziewicz J, Gabrilovich DI, Varga G, etal Induction of potent human immunodeficiency virus Type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J. Viral 75(16), 7621–7628 (2001).
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L, et al Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415(6869), 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• •Several vaccine vector delivery systems were compared as preventive vaccine with respect to induction of Sly-specific immunity and control of viral replication following infection with pathogenic SW. The animals immunized with a replication-defective recombinant adenovector exhibited the most pronounced attenuation of the virus replication.
   Google Scholar
• Barouch DH, Santra S, Schmitz JE, etal. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290(5491), 486–492 (2000).
   PubMed Web of Science ®Google Scholar
• Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Med. 6(9), 951–955 (2000).
   PubMed Web of Science ®Google Scholar
• Hanke T, Neumann VC, Blanchard TJ, etal Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 17(6), 589–596 (1999).
   PubMed Web of Science ®Google Scholar
• Pal R, Venzon D, Letvin NL, etal. ALVAC-simian model of HIV infection-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus simian model of HIV infectionmac-induced immunodeficiency. J. Vim!. 76(1), 292–302 (2002).
   Google Scholar
• Tryniszewska E, Nacsa J, Lewis MG, et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J. Immund 169(9), 5347–5357 (2002).
   PubMed Web of Science ®Google Scholar
• Champagne P, Ogg GS, King AS, etal. Skewed maturation of memory HIV-specific CD8 T-lymphocytes. Nature 410(6824), 106–111 (2001).
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T-cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8(4), 379–385 (2002).
   PubMed Web of Science ®Google Scholar
• van Baarle D, Kostense S, Hovenkamp E, etal Lack of Epstein-Barr virus-and HIV-specific CD27-CD8+ T-cells is associated with progression to viral disease in HIV-infection. 4IDS16 (15), 2001-2011 (2002).
   Google Scholar
• Oxenius A, Fidler S, Brady M, etal Variable fate of virus-specific CD4(+) T-cells during primary HIV-1 infection. Eur j Immund 31(12), 3782–3788 (2001).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Kunstman J, Kuroda MJ, etal. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 415(6869), 335–339 (2002).
   PubMed Web of Science ®Google Scholar
• Frost SD, Martinez-Picado J, Ruiz L, Clotet B, Brown AJ. Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus Type 1 infection. J. Viral. 76(3), 968–979 (2002).
   PubMed Web of Science ®Google Scholar
• Oxenius A, McLean AR, Fischer M, etal Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J. Vim!.76(20), 10169–10176 (2002).
   Google Scholar
• Oxenius A, Price DA, Gunthard HF, etal Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc. Natl Acad. Sci. USA 99(21), 13747–13752 (2002).Affiliations
   PubMed Web of Science ®Google Scholar